Latest News and Press Releases

Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP February 20, 2024, 7:00...

Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam,...

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected...

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced...

ADDRESS study did not meet primary or secondary endpoints Pemphigus deprioritized as efgartigimod indicationUpdate on BALLAD study GO/NO GO decisionConference call scheduled for today, December 20,...

Study did not meet primary or secondary endpointsFavorable safety and tolerability profile consistent with previous clinical trials Conference call scheduled for today, November 28, 2023 at 8:30am...

VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe argenx is committed to continued collaboration with local authorities across the region to...

Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized...

November 1, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...

$329 million in third quarter global net product salesOn track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host...